BioLineRx (BLRX) Total Current Liabilities (2012 - 2025)

BioLineRx's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $12.1 million for Q4 2025.

• In Q4 2025, Total Current Liabilities fell 21.31% year-over-year to $12.1 million; the TTM figure through Dec 2025 stood at $12.1 million (down 21.31% YoY), while the FY2025 annual figure was $12.1 million, down 21.31% from the prior year.
• Total Current Liabilities was $12.1 million for Q4 2025 at BioLineRx, down from $13.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $42.8 million in Q4 2023 to a low of $8.1 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $15.9 million across 5 years, with a median of $12.3 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 300.64% in 2023, then tumbled 63.99% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $9.7 million in 2021, then gained by 9.88% to $10.7 million in 2022, then surged by 300.64% to $42.8 million in 2023, then sank by 63.99% to $15.4 million in 2024, then decreased by 21.31% to $12.1 million in 2025.
• The last three Total Current Liabilities figures came in at $12.1 million (Q4 2025), $13.7 million (Q3 2025), and $15.5 million (Q2 2025), per Business Quant data.